A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders

Haemophilia

Volumn 8, Issue 2, 2002, Pages 129-135

  Schulman, S ^a   Kinnman, N ^a   Lindmarker, P ^a   von Sydow, M ^b  

^a Department of Hematology ^*  (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Duration; Haemophilia; Hepatitis C; Interferon; Ribavirin; von Willebrand disease

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RNA; ALPHA2B INTERFERON; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING DISORDER; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; EMOTIONAL DISORDER; EPISTAXIS; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; MALE; MENORRHAGIA; NAUSEA; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; THYROTOXICOSIS; VON WILLEBRAND DISEASE; WEIGHT REDUCTION; BLOOD CLOTTING DISORDER; DISEASE TRANSMISSION; DRUG ADMINISTRATION; DRUG COMBINATION; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BLOOD COAGULATION DISORDERS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

EID: 0036489623     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00629.x     Document Type: Article

References (18)

1. Widell A, Hansson BG, Berntorp E et al. Antibody to a hepatitis C virus related protein among patients at high risk for hepatitis B. Scand J Infect Dis 1991; 23: 19-24.
2. Schulman S, Grillner L. Antibodies against hepatitis C in a population of Swedish haernophiliacs and heterosexual partners. Scand J Infect Dis 1990; 22: 393-7.
3. Seeff LB, Buskell-Bales Z, Wright EC et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung and Blood Institute Study Group. N Engl J Med 1992; 327: 1906-11.
4. Datz C, Cramp M, Haas T et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut 1999; 44: 563-7.
5. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26: 34-8S.
6. Carithers RLJ, Emerson SS. Meta-analysis of interferon alfa-2b-trials. Hepatology 1997; 26: 83-8S.
7. Reichard O, Norkrans G, Frydén A et al. Double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
8. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.
9. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
10. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
11. Rumi MG, Santagostino E, Morfini M et al. A multi-centre controlled, randomized, open trial of interferon alpha 2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Blood 1997; 89: 3529-33.
12. Meili EO, Marbet GA, Peter K, Fried R, the Medical Committee of the Swiss Hemophilia Association. Chronic hepatitis C in hemophiliacs - combined treatment with interferon/ribavirin. Ann Hematol 2000; 79 (Suppl. 1): A35 (Abstract).
13. Lethagen S, Widell A, Berntorp E, Verbaan H, Lindgren S. Clinical spectrum of hepatitis C-related disease and response to treatment with interferon'and ribavirin in haemophilia or von Willebrand disease. Br J Haematol 2001; 113: 87-93.
14. Sauleda S, Esteban JI, Altisent C, Puig L, Esteban R, Guardia J. Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C. Thromb Haemost 2000; 83: 807-10.
15. Lauer GM, Walker 13D. Hepatitis C virus infection. N Engl J Med 200 1; 345: 41-52.
16. Fontaine H, Chaix M-L, Lagneau J-L, Bréhot C, Pol S. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa. Lancet 2000; 356: 41 (letter).
17. Toyoda H, Kumada T, Tokuda A et al. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. J Viral Hepatitis 2000; 7: 414-9.
18. Schulman S, Ericzon B-G, Eleborg L. Modification of von Willebrand Disease after liver transplantation. Thromb Haemost 2001; 86: 1588-9(letter).